SWOG clinical trial number
CTSU/A021101

Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study

Closed
Phase
Published
Abbreviated Title
FOLFIRINOX + ChemoRT + Surgery + Gemcitabine for Pts w/Borderline Resectable Pancreatic Adenocarcinoma
Activated
05/15/2013
Closed
08/27/2014
Participants
CTSU, Limited: Institutions Listed on the Title Page

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Gemcitabine hydrochloride Irinotecan Leucovorin Calcium Oxaliplatin Radiation Therapy Surgery Capecitabine

Publication Information Expand/Collapse

2016

Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101

MHG Katz;Q Shi;SA Ahmad;JM Herman;R Marsh;E Collisson;L Schwartz;W Frankel;R Martin;W Conway;M Truty;H Kindler;AM Lowy;T Behaii-Saab;PA Philip;M Talamonti;D Cardin;N LoConte;P Chen;J Hoffman;AP Venook JAMA Surgery Jun 8:e161137

PMid: PMID27275632 | PMC number: PMC5210022

2015

Intergroup pilot study of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by capecitabine-based chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101

MHG Katz;Q Shi;SA Ahmad;J Herman;R Marsh;E Collisson;L Schwartz;H Kindler;AM Lowy;AP Venook Journal of Clinical Oncology 33:5s (suppl; abstr 4008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;

2013

Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design

MHG Katz;R Marsh;JM Herman;Q Shi;E Collison;AP Venook;HL Kindler;SR Alberts;PA Philip;AM Lowy;PWT Pisters;MC Posner;JD Berlin;SA Ahmad Annals of Surgical Oncology 20(8):2787-2795

PMid: PMID23435609 | PMC number: PMC5600517

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase